Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...

Since being approved, Wegovy's popularity has soared, to the point where the drug has made its maker, Novo Nordisk -- for ...

One of the biggest gripes around weight loss medications like Wegovy and Zepbound is the high price tag. At $1,000 or more a ...

Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...

Eli Lilly shares have room to keep going as GLP-1 drugs spread their reach.

Let’s delve into the details of each of the evaluated factors, but first, for a quick background: With a $917 Bil market cap, ...

The race to develop the next generation of weight loss drugs has taken an interesting new turn. In recent research, Eli Lilly ...

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...

Novo Nordisk and Eli Lilly denied weight-loss drug partnership with Mangoceuticals on Thursday, hours after the telehealth ...

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and ...

Novo Nordisk and Eli Lilly deny partnership with Mangoceuticals for weight-loss drugs, causing Mangoceuticals' shares to ...